AR125827A1 - Métodos para minimizar la neurotoxicidad asociada a la terapia con células t del receptor de antígeno quimérico (car) - Google Patents
Métodos para minimizar la neurotoxicidad asociada a la terapia con células t del receptor de antígeno quimérico (car)Info
- Publication number
- AR125827A1 AR125827A1 ARP220101236A ARP220101236A AR125827A1 AR 125827 A1 AR125827 A1 AR 125827A1 AR P220101236 A ARP220101236 A AR P220101236A AR P220101236 A ARP220101236 A AR P220101236A AR 125827 A1 AR125827 A1 AR 125827A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- administration
- car
- cell therapy
- antigen receptor
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 206010044221 Toxic encephalopathy Diseases 0.000 title abstract 4
- 206010029350 Neurotoxicity Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000007135 neurotoxicity Effects 0.000 title abstract 3
- 231100000228 neurotoxicity Toxicity 0.000 title abstract 3
- 238000002659 cell therapy Methods 0.000 title abstract 2
- 210000005259 peripheral blood Anatomy 0.000 abstract 3
- 239000011886 peripheral blood Substances 0.000 abstract 3
- 238000011357 CAR T-cell therapy Methods 0.000 abstract 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract 2
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Un método para reducir la neurotoxicidad asociada con la terapia de células T con receptor de antígeno quimérico (CAR), dicho método caracterizado porque comprende: administrar la terapia de células T con CAR a un sujeto; determinar una o más de (i) la carga tumoral del sujeto antes de dicha administración, (ii) los niveles de IL-6 del sujeto al momento de dicha administración, (iii) la expansión de las células T con CAR en dicho sujeto después de dicha administración, (iv) la persistencia de las células T con CAR en sangre periférica de dicho sujeto después de dicha administración, (v) el desarrollo del síndrome de liberación de citocinas (CRS) de grado ³ 2 en dicho sujeto después de dicha administración, (vi) el desarrollo del síndrome de neurotoxicidad asociado a células efectoras inmunitarias (ICANS) en dicho sujeto después de dicha administración, (vii) los niveles pico de IL-6 en sangre periférica en dicho sujeto después de dicha administración, (viii) los niveles pico de INF-g en sangre periférica en dicho sujeto después de dicha administración; y (iv) recuento de linfocitos en dicho sujeto después de dicha administración; y administrar una mitigación terapéutica a dicho sujeto, basada en dicha determinación, para reducir la neurotoxicidad asociada a la terapia de células T con CAR.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163186872P | 2021-05-11 | 2021-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125827A1 true AR125827A1 (es) | 2023-08-16 |
Family
ID=81850771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101236A AR125827A1 (es) | 2021-05-11 | 2022-05-10 | Métodos para minimizar la neurotoxicidad asociada a la terapia con células t del receptor de antígeno quimérico (car) |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230061503A1 (es) |
EP (1) | EP4337959A1 (es) |
JP (1) | JP2024518549A (es) |
KR (1) | KR20240026124A (es) |
CN (1) | CN117616279A (es) |
AR (1) | AR125827A1 (es) |
AU (1) | AU2022272021A1 (es) |
BR (1) | BR112023023269A2 (es) |
CA (1) | CA3217687A1 (es) |
IL (1) | IL308345A (es) |
MX (1) | MX2023013421A (es) |
TW (1) | TW202309523A (es) |
WO (1) | WO2022238901A1 (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1002023A (en) | 1909-06-03 | 1911-08-29 | Arthur T Beach | Rotary pump. |
US8028060B1 (en) | 2007-01-05 | 2011-09-27 | Apple Inc. | Background task execution over a network based on network activity idle time |
CN104239134B (zh) | 2013-06-21 | 2018-03-09 | 华为技术有限公司 | 一种众核系统的任务管理方法和装置 |
JP6452264B2 (ja) | 2014-05-22 | 2019-01-16 | ヴアブコ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツングWABCO GmbH | 空気ばね式の自動車の車高を制御するための方法 |
US10507219B2 (en) * | 2014-10-20 | 2019-12-17 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
EP3384294B1 (en) * | 2015-12-04 | 2021-10-13 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
KR102511914B1 (ko) | 2016-08-04 | 2023-03-21 | 삼성전자주식회사 | 자기 기억 소자 및 이의 제조 방법 |
CN106869907B (zh) | 2017-01-19 | 2019-08-06 | 中国科学院地质与地球物理研究所 | 基于电场理论的近钻头无线短传地面环境下标定方法 |
CA3065120A1 (en) * | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
WO2019109053A1 (en) * | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
-
2022
- 2022-05-10 AU AU2022272021A patent/AU2022272021A1/en active Pending
- 2022-05-10 EP EP22726177.3A patent/EP4337959A1/en active Pending
- 2022-05-10 US US17/740,665 patent/US20230061503A1/en active Pending
- 2022-05-10 KR KR1020237038933A patent/KR20240026124A/ko unknown
- 2022-05-10 WO PCT/IB2022/054342 patent/WO2022238901A1/en active Application Filing
- 2022-05-10 AR ARP220101236A patent/AR125827A1/es unknown
- 2022-05-10 BR BR112023023269A patent/BR112023023269A2/pt unknown
- 2022-05-10 MX MX2023013421A patent/MX2023013421A/es unknown
- 2022-05-10 IL IL308345A patent/IL308345A/en unknown
- 2022-05-10 CA CA3217687A patent/CA3217687A1/en active Pending
- 2022-05-10 JP JP2023570153A patent/JP2024518549A/ja active Pending
- 2022-05-10 CN CN202280033168.5A patent/CN117616279A/zh active Pending
- 2022-05-10 TW TW111117445A patent/TW202309523A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112023023269A2 (pt) | 2024-01-30 |
MX2023013421A (es) | 2023-12-06 |
JP2024518549A (ja) | 2024-05-01 |
KR20240026124A (ko) | 2024-02-27 |
US20230061503A1 (en) | 2023-03-02 |
CN117616279A (zh) | 2024-02-27 |
EP4337959A1 (en) | 2024-03-20 |
AU2022272021A1 (en) | 2023-11-30 |
CA3217687A1 (en) | 2022-11-17 |
WO2022238901A1 (en) | 2022-11-17 |
IL308345A (en) | 2024-01-01 |
TW202309523A (zh) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2756336T3 (es) | Métodos que modulan el efecto inmunorregulador de las células madre | |
Musch et al. | T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase | |
RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
US9616106B2 (en) | IL-12 for radiation protection and radiation-induced toxicity mitigation | |
Myers et al. | Kaposi sarcoma in kidney transplant recipients | |
Fritzell et al. | Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion | |
ES2397854T3 (es) | Inmunoterapia para pacientes con inmunosupresión | |
Raza et al. | A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome | |
JP2009197032A (ja) | 免疫抑制を逆転させるための免疫治療 | |
Uygur et al. | Leflunomide—an immunomodulator—induces regression of endometrial explants in a rat model of endometriosis | |
Nenclares et al. | Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations | |
AR125827A1 (es) | Métodos para minimizar la neurotoxicidad asociada a la terapia con células t del receptor de antígeno quimérico (car) | |
Dammeijer et al. | Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy | |
Hock et al. | Donor CD4 T cells trigger costimulation blockade-resistant donor bone marrow rejection through bystander activation requiring IL-6 | |
Barret et al. | 13 Total body irradiation | |
MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
Wang et al. | rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells | |
ITTO20070480A1 (it) | Impiego di pidotimod, somministrato per via intranasale per potenziare la risposta immunitaria umorale e cellulare antigene-specifica | |
WO2019126384A1 (en) | Effective il-12 dosing regimens | |
Srikanth et al. | Enhanced regression of tumors in mice with combined chemotherapy and immunotherapy | |
US20240110174A1 (en) | Compositions, systems, and methods for treating cancer using alternating electric fields and dendritic cells | |
Khamar | Small cell carcinoma of the urinary bladder successfully managed with palliative radiotherapy and immunotherapy | |
Mensurado | Regulation of T cell fitness and functions in tumour responses | |
Romano et al. | Advances in understanding regulatory myeloid cells | |
Yegorov et al. | ATIM-34. SINGLE-CELL RNA SEQUENCING REVEALS DYNAMIC IMMUNE RESPONSE CHANGES IN GLIOBLASTOMA PATIENT WITH DURABLE COMPLETE RESPONSE TO CMV PP65-LAMP RNA-PULSED DENDRITIC VACCINES |